Tech Company Financing Transactions
EpiVax Funding Round
SV Health Investors participated in a capital raise for EpiVax. The financing round closed on 4/6/2026.
Transaction Overview
Company Name
Announced On
4/6/2026
Transaction Type
Venture Equity
Amount
Unknown
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
188 Valley Street 424
Providence, RI 02909
USA
Providence, RI 02909
USA
Phone
Website
Email Address
Not Recorded
Overview
EpiVax partners with biologic and vaccine developers to manage immunogenicity risk throughout the product lifecycle. We leverage deep scientific expertise to develop and apply industry leading in silico analyses and in vitro approaches to generate actionable immunogenicity data. These insights help our partners reduce uncertainty, mitigate risks, and use resources more efficiently while building regulatory-ready strategies for safer, more effective therapies.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Rich-Henry Schabowsky
Chief Financial Officer
Brad Crevier
Chief Scientific Officer
Christine Boyle
Chief Scientific Officer
Vibha Jawa
Chief Technical Officer
Guilhem Richard
VP - Bus. Development
Sarah Moniz
VP - Engineering
Matthew Ardito
VP - Human Resources
Leaya Martelli
Browse more venture capital transactions:
Prev: 4/3/2026: Uphold venture capital transaction
Next: 4/6/2026: Mezza venture capital transaction
Share this article
Where The Data Comes From
We do our best to document all VC transactions involving tech companies. VC investment data records on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs